Patients with symptomatic chronic obstructive pulmonary disease (COPD) are commonly
treated with inhaled medications that fall into three classes: beta-agonists, muscarinic …

BACKGROUND: Anticholinergics and β2-agonists have generally been considered
equivalent choices for bronchodilation in chronic obstructive pulmonary disease (COPD) …

Objective: To determine whether a combined formulation consisting of ipratropium and an
inhaled β2 agonist (2-in-1 therapy) leads to lower respiratory-related healthcare use and …

Background: Although airflow limitation improved by inhaled anticholinergic drugs varies
among individuals with chronic obstructive pulmonary disease (COPD), the relationship …

Chronic obstructive pulmonary disease (COPD) is a substantial health burden.
Cardiovascular disease (CVD), the leading cause of death, frequently coexists with COPD …

Long-acting bronchodilators are recommended as maintenance therapy for chronic
obstructive pulmonary disease (COPD)(1). Dual therapy using long-acting muscarinic …

Background To estimate the potential cost savings by following the current Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being …

Regular short-acting inhaled β-agonist therapy is of uncertain benefit in patients with chronic
obstructive pulmonary disease (COPD). We conducted a randomized, concealed, double …

OBJECTIVES: In light of recent results from observational studies showing prolonged
survival in subjects taking long-acting β2-agonists (LABA) and/or inhaled corticosteroids …

Objective: Bronchodilator maintenance treatment improves pulmonary function and health-
related quality of life in COPD patients. Pulmonary function and patient …